Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Nanobiotix S.A. ADR (NBTX)

Nanobiotix S.A. ADR (NBTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nanobiotix: Voting Rights and Shares Capital of the Company Business Wire - Mon Oct 10, 2022

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022 Business Wire - Wed Sep 28, 2022

Regulatory News:

NBTX : 3.35 (-3.46%)
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022 Business Wire - Thu Sep 22, 2022

Regulatory News:

NBTX : 3.35 (-3.46%)
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy Business Wire - Wed Sep 21, 2022

Regulatory News:

NBTX : 3.35 (-3.46%)
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024 Business Wire - Mon Sep 12, 2022

Regulatory News:

NBTX : 3.35 (-3.46%)
Nanobiotix: Voting Rights and Shares Capital of the Company Business Wire - Thu Sep 8, 2022

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer Business Wire - Wed Sep 7, 2022

Regulatory News:

NBTX : 3.35 (-3.46%)
LIAN : 0.3190 (-8.28%)
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences Business Wire - Tue Sep 6, 2022

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022 Business Wire - Wed Aug 31, 2022

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)
NANOBIOTIX: Voting Rights and Shares Capital of the Company Business Wire - Tue Aug 9, 2022

Regulatory News:

NANO : 35.33 (-0.81%)
NBTX : 3.35 (-3.46%)

Barchart Exclusives

Will U.S. Bonds Keep Falling? Barchart - Thu Nov 28, 2:00PM CST
The U.S. Fed has cut the short-term Fed Funds Rate by 75 basis points since September 2024 and has told markets that more monetary policy easing is on the horizon. Meanwhile, longer-term rates continue to ignore the short-term rates as they climb to higher levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot